Exploring new medicines from fungi using advanced genetic tools
Advancing CRISPR-Cas Technologies for the Discovery and Characterization of Novel Fungal Natural Products
This study is exploring how to find new medicines from fungi that could help patients by using advanced techniques to unlock special compounds, aiming to create better treatments for various health conditions.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pennsylvania NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project ID | NIH-10841671 on NIH RePORTER |
What this research studies
This research focuses on discovering new bioactive compounds from fungi that could lead to novel medications. By utilizing CRISPR-Cas genome editing technologies, the team aims to identify and characterize unique fungal natural products, particularly a class of compounds known as ribosomally synthesized and post-translationally modified peptides (RiPPs). The project involves developing innovative pipelines to prioritize and manipulate fungal gene clusters, which will enhance the ability to produce and study these compounds. Patients may benefit from new treatments derived from these discoveries.
Who could benefit from this research
Good fit: Ideal candidates for participation or benefit from this research would include individuals with conditions that currently lack effective treatments or those who may benefit from novel therapeutic agents derived from fungal natural products.
Not a fit: Patients with conditions that are not addressed by fungal-derived therapies may not receive any benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of new drugs for treating various human diseases.
How similar studies have performed: Other research has shown promise in utilizing CRISPR technologies for drug discovery, indicating that this approach could lead to significant advancements in the field.
Where this research is happening
Philadelphia, United States
- University of Pennsylvania — Philadelphia, United States (Active)
Researchers
- Principal investigator: Gao, Xue — University of Pennsylvania
- Study coordinator: Gao, Xue
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.